Email Us
Call Us
AUSTIN, Texas – August 23, 2026 – A preclinical study conducted at Altogen Labs under an IACUC-approved protocol has been published in the peer-reviewed journal Life, providing in vivo evidence that Turn Therapeutics’ investigational topical therapy GX-03 selectively reduces inflammatory signals associated with inflammatory skin disease.
The study evaluated 40 mice receiving either no pretreatment or four days of topical GX-03 before standardized Staphylococcus aureus exposure, with 18 animals per group included in the final analysis following predefined exclusions. GX-03 pretreatment reduced mean clinical disease severity from a vIGA-AD score of 2.44 in untreated animals to 0.83, a 66.0% reduction. IL-36α expression decreased by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%, while IL-13 did not differ significantly between groups. No local irritation, dryness, redness, barrier disruption, or other adverse skin findings were observed during the pretreatment period. The selectivity of that cytokine pattern is scientifically important – and it is only detectable in a study with sufficient statistical power, consistent induction, and clean analytical work. The reported design, with predefined exclusions and blinded clinical scoring, reflects the standards Altogen Labs applies to every sponsor program.
Altogen Labs supports development-stage and publicly traded biopharmaceutical companies from early proof of concept through IND-enabling packages, delivering complete study documentation and full statistical analysis, with 100% of intellectual property retained by the sponsor.
About Altogen Labs Altogen Labs is a professional, experienced, and highly reputable GLP-compliant contract research organization providing preclinical research services and biology CRO services to pharmaceutical companies, biotechnology firms, and academic institutions worldwide. The company maintains a large collection of in-house validated xenograft models — CDX, PDX, syngeneic, organoids, and NAMs — and extensive experience in efficacy xenograft studies and safety toxicology studies supporting IND applications and regulatory submissions.
Contact Information: Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com
Source citation: Turn Therapeutics Inc. (Nasdaq: TTRX), “Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch,” Business Wire, August 20, 2026, states that the study was conducted at Altogen Labs under an IACUC-approved protocol. Publication: Burnam B, Bresnick S., Life, 2026, DOI: 10.3390/life16081369.